Posterior zone I retinopathy of prematurity: spectrum of disease and outcome after laser treatment

Katoch, Deeksha; Dogra, Mangat R; Aggarwal, Kanika; Sanghi, Gaurav; Samanta, Ramanuj; Handa, Sabia; Dogra, Mohit

doi:10.1016/j.jcjo.2018.03.005

Cited by 25 publications

(36 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Structural outcomes of conventional laser monotherapy for zone 1 APROP are poor with more than 50% of eye progressing to stage 5 even after adequate laser. [ 24 ] This study had 30 eyes with zone 1 posterior APROP at final analysis and 25 eyes (83.3%) achieved favorable outcomes after combined IVR and laser therapy. Findings from our study substantiate that, combination therapy for eyes with zone 1 posterior APROP has better structural outcomes than laser monotherapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity

Gangwe¹,

Agrawal

Gangrade³

et al. 2021

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: The aim of this study was to report the treatment outcomes of early and deferred laser in infants of aggressive posterior retinopathy of prematurity (APROP) after initial treatment with intravitreal Ranibizumab (IVR). Methods: In a prospective, randomized, interventional study, infants with APROP received IVR (0.25 mg) and were randomized into two groups prior to laser. Laser was done at 1 week (group 1) or at 6 weeks or earlier if there was a recurrence of plus disease (group 2). The structural outcome, number of laser spots, duration of laser procedure and refractive error at 6 months were compared. Favorable structural outcome was defined as, complete regression of disease at 6 weeks after laser. Results: 63 eyes of 32 infants with APROP were enrolled. Mean gestational age (GA) and birth weight (BW) were 30.2 ± 2.3 weeks and 1294 ± 372.8 grams respectively. GA, BW, and disease severity were comparable at baseline. 27 (90%) eyes in group 1 and 29 (93.5%) eyes in group 2 had favorable structural outcome ( P = 0.61) at 6 weeks after laser. Eyes in group 2 (2149.8 ± 688.7) required lesser number of laser spots than group 1 (2570.8 ± 615) ( P = 0.01). At six months, more eyes in group 1 had myopic refractive error (Mean spherical equivalent: –1.0D ± 1.3) than those in group 2 (Mean spherical equivalent: 0.5D ± 1.9) ( P = 0.002). Conclusion: Infants with APROP receiving IVR have comparable structural outcomes after an early or deferred laser. Moreover, eyes undergoing deferred laser require less number of laser spots and have a less myopia at 6 months after laser.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Findings from our study substantiate that, combination therapy for eyes with zone 1 posterior APROP has better structural outcomes than laser monotherapy. [ 24 ]…”

Section: Discussionmentioning

confidence: 99%

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity

Gangwe¹,

Agrawal

Gangrade³

et al. 2021

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Posterior zone I ROP has been shown to have very poor outcome with laser alone and a combination treatment with anti-VEGF may be a better option in such eyes. [37]…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of 532 nm frequency-doubled Nd-YAG green laser photocoagulation for treatment of retinopathy of prematurity

Singh

Katoch

Handa

et al. 2019

Indian J Ophthalmol

Self Cite

View full text Add to dashboard Cite

Purpose: To evaluate the safety and efficacy of 532 nm frequency-doubled Nd-YAG green laser for treatment of retinopathy of prematurity (ROP). Methods: This retrospective interventional case series included infants undergoing treatment for ROP with 532 nm green laser between January 2012 and March 2017 at a single tertiary-care referral center. Review of clinical records was done to identify baseline ROP characteristics, procedural difficulties, complications related to the laser procedure and outcome of treatment at ≥ 1 year of follow-up. Results: There are about 347 eyes of 182 infants were included in this present study. ROP presented in zone I in 76 eyes (21.9%) and zone II in 271 eyes (78.1%). Tunica vasculosa lentis (TVL) was present in 43.8% and pre-existing vitreous hemorrhage in 4.6% of the eyes. 532 nm green laser could be performed as a primary procedure in all eyes, including those with TVL. 322 eyes completed a minimum follow up of 1 year with a mean follow up of 22.8 months (range, 12–54 months). At the last follow-up visit, 298 (92.5%) of the 322 eyes had a favorable outcome. On logistic regression analysis, pre-existing fibrovascular proliferation ( p = 0.04) and new-onset fibrovascular proliferation after treatment ( p = 0.001) were the most significant independent predictors of poor outcome. Complications encountered were new-onset hemorrhage in 36 eyes (11.2%), anterior segment ischemia in two eyes (0.006%) and cataract in one eye (0.003%). Conclusion: 532 nm frequency-doubled Nd-YAG green laser appears to be safe and effective in the treatment of ROP.

show abstract

“…Studies have shown poor outcomes in the zone I ROP, especially in postzone I disease. [3] Moreover what were the predictors of unfavorable outcome in this study? Did they have any preretinal hemorrhage before treatment or early-onset fibrovascular proliferation just after laser photocoagulation, which has been cited as poor predictors in APROP despite laser in literature.…”

mentioning

confidence: 90%

Posterior zone I retinopathy of prematurity: spectrum of disease and outcome after laser treatment

Cited by 25 publications

References 31 publications

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity

Safety and efficacy of 532 nm frequency-doubled Nd-YAG green laser photocoagulation for treatment of retinopathy of prematurity

Comment on “bevacizumab or laser for aggressive posterior retinopathy of prematurity”

Contact Info

Product

Resources

About